Figure 2
Figure 2. Kinetics of clot contraction in whole blood. Curves tracking changes in the size of contracting clots formed in citrated whole blood. (A) Samples were clotted with 1 U/mL thrombin in the presence of 0, 2, 5, and 10 mM CaCl2. (B) Samples were clotted with 0.5 or 1 U/mL of thrombin and 2 mM CaCl2. (C-F) Samples were clotted with 1 U/mL and 2 mM CaCl2. (C) Myosin IIA was inhibited through the addition of blebbistatin at 25, 50, 100, and 200 μM final concentrations. (D) Fibrin-platelet interactions were impaired by adding RGDS at 0.5, 1, and 2 mM final concentrations. (E, F) Cross-linking of fibrin was suppressed with 1 mM iodoacetamide (E) and 0.1, 0.5, 1.0, and 2.0 mM cystamine (F).

Kinetics of clot contraction in whole blood. Curves tracking changes in the size of contracting clots formed in citrated whole blood. (A) Samples were clotted with 1 U/mL thrombin in the presence of 0, 2, 5, and 10 mM CaCl2. (B) Samples were clotted with 0.5 or 1 U/mL of thrombin and 2 mM CaCl2. (C-F) Samples were clotted with 1 U/mL and 2 mM CaCl2. (C) Myosin IIA was inhibited through the addition of blebbistatin at 25, 50, 100, and 200 μM final concentrations. (D) Fibrin-platelet interactions were impaired by adding RGDS at 0.5, 1, and 2 mM final concentrations. (E, F) Cross-linking of fibrin was suppressed with 1 mM iodoacetamide (E) and 0.1, 0.5, 1.0, and 2.0 mM cystamine (F).

Close Modal

or Create an Account

Close Modal
Close Modal